Predicting Drug Targets in Human Cancers.

Introduction: A large amount of knowledge has accumulated regarding the pharmacology of most cancer types, including their side effects, and during the last decade, many novel agents have emerged, accompanied by increased costs for healthcare systems. Aim: Artificial intelligence (AI) was applied in...

Descripción completa

Detalles Bibliográficos
Publicado en:Journal of Clinical Pharmacy & Therapeutics Vol. 2025; pp. 1 - 29
Autores principales: Guzmán, David Calderón, Brizuela, Norma Osnaya, Peraza, Armando Valenzuela, Herrera, Maribel Ortiz, Garcia, Diego E. Ortega, Olguin, Hugo Juarez, Mejía, Gerardo Barragán, Hasnain, Md Saquib
Formato: pictorial review tables/charts Journal Article
Publicado: Wiley-Blackwell 11/26/2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189588329&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 189588329
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        02694727
        EV4
      jtl: Journal of Clinical Pharmacy & Therapeutics
      issn: 02694727
      maglogo: Y
    pubinfo:
      dt: 11/26/2025
      vid: 2025
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        189588329
        189588329
        189588329
        10.1155/jcpt/4853636
        189588329
      ppf: 1
      ppct: 28
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: C
          – @attributes:
              type: P
      tig:
        atl: Predicting Drug Targets in Human Cancers.
      aug:
        au:
          Guzmán, David Calderón
          Brizuela, Norma Osnaya
          Peraza, Armando Valenzuela
          Herrera, Maribel Ortiz
          Garcia, Diego E. Ortega
          Olguin, Hugo Juarez
          Mejía, Gerardo Barragán
          Hasnain, Md Saquib
        affil: Neuroscience Laboratory,, National Paediatric Institute,, Ministry of Health,, Mexico City, Mexico, moh.koshi.gov.np
      sug:
        subj:
          Neoplasms Drug Therapy
          Antineoplastic Agents Therapeutic Use
          Artificial Intelligence
          Small Molecules
          Prediction Models
          Biological Factors
          United States
          Cancer Patients
          Computer-Aided Design
          Drug Design
          Drug Discovery
          Carrier Proteins
          Predictive Value of Tests
          Prediction Algorithms
          Drug Compounding
          Health Care Costs
          Chemotherapy, Cancer
      ab: Introduction: A large amount of knowledge has accumulated regarding the pharmacology of most cancer types, including their side effects, and during the last decade, many novel agents have emerged, accompanied by increased costs for healthcare systems. Aim: Artificial intelligence (AI) was applied in healthcare services, and the benefit of its use in the prediction of the targets of low molecular weight compounds that can affect biological processes was assessed (proportion of the top predicted targets, common name, target class and probability). Method: Designing the chemical agent or molecule chosen and the program will give the protein target prediction immediately by AI. A tuning algorithm device, with new information input in the web application interface, was used. Results: Information was arranged in order and fed to an in silico target prediction/Swiss TargetPrediction (STP). This tool is a computational method used to predict the most probable protein targets of small molecules, as well as to envisage what happens when many chemotherapy drugs are combined in cancer treatment. It aids in understanding some molecular processes controlling specific physical traits or biological activities to elucidate probable beneficial and adverse consequences. In addition, it helps to predict imprecision of defined molecules and pave the way to drug repositioning. Prediction is carried out employing the ligand‐based drug design (LBDD), which enables comparison of the correlation between the molecule under examination and the known binding molecules of a large set of target proteins. Conclusion: Target activity profiles enable a systematic repurposing process by extending the target profile of drugs, and then drug repurposing with AI provides a cost‐effective strategy to reuse approved drugs for new medical indications and the availability of new treatments, reduces development costs and mitigates risks due to the cost of the cancer drug agents, coupled with high cancer disease prevalence, which means the current cost trajectory is untenable for most world healthcare systems.
      pubtype: Academic Journal
      doctype:
        pictorial
        review
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N